Reports
Global Hereditary Angioedema Therapeutic Market: By Drug Class: C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others; By Treatment Type; By Route of Administration; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Hereditary Angioedema Therapeutic Market Outlook
The global hereditary angioedema therapeutic market was estimated at USD 3.19 billion in 2022 and is predicted to grow at a CAGR of 8.90% in the forecast period of 2023-2028 to achieve USD 5.32 billion by 2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Globally, the rising cases of hereditary angioedema (HAE) is a key driver of the market. The condition affects between 1-9 individuals per 100,000 population, according to the National Organization for Rare Disorders (NORD). Due to underreporting and misdiagnosis, the actual number of people with the condition is significantly higher.
Market Segmentation
The hereditary angioedema therapeutic industry can be divided based on segments like drug class, treatment type, and route of administration.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on drug class into:
- C1-Esterase Inhibitor
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
The industry can be divided based on treatment types as:
- Prophylaxis Treatment
- On-Demand Treatment
The industry can be classified based on the route of administration:
- Intravenous
- Subcutaneous
- Oral
The EMR report looks into the regional markets of hereditary angioedema therapeutic like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The hereditary angioedema therapeutic market is being driven by the increasing awareness-raising activities among the general population. The lack of awareness of hereditary angioedema therapeutic is the main reason for misdiagnosis, which in turn results in patients receiving insufficient care. Some patients with hereditary angioedema are misdiagnosed with appendicitis, gastrointestinal disorders, and other non-allergic angioedema conditions. A small number of patients misdiagnosed for the disorder provides a large pool of patients with significant medical needs. This is expected to be a key market driver for hereditary angioedema therapeutic in the coming years.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global hereditary angioedema therapeutic market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Takeda Pharmaceutical Company Limited
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group N.V.
- CSL Limited
- Attune Pharmaceuticals, Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Treatment Type , Route of Administration, Region |
| Breakup by Drug Class | C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others |
| Breakup by Treatment Type | Prophylaxis Treatment, On-Demand Treatment |
| Breakup by Route of Administration | Intravenous, Subcutaneous, Oral |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Attune Pharmaceuticals, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Hereditary Angioedema Therapeutic Market Analysis
8.1 Key Industry Highlights
8.2 Global Hereditary Angioedema Therapeutic Historical Market (2018-2022)
8.3 Global Hereditary Angioedema Therapeutic Market Forecast (2023-2028)
8.4 Global Hereditary Angioedema Therapeutic Market by Drug Class
8.4.1 C1-Esterase Inhibitor
8.4.1.1 Historical Trend (2018-2022)
8.4.1.2 Forecast Trend (2023-2028)
8.4.2 Bradykinin B2 Receptor Antagonist
8.4.2.1 Historical Trend (2018-2022)
8.4.2.2 Forecast Trend (2023-2028)
8.4.3 Kallikrein Inhibitor
8.4.3.1 Historical Trend (2018-2022)
8.4.3.2 Forecast Trend (2023-2028)
8.4.4 Others
8.5 Global Hereditary Angioedema Therapeutic Market by Treatment Type
8.5.1 Prophylaxis Treatment
8.5.1.1 Historical Trend (2018-2022)
8.5.1.2 Forecast Trend (2023-2028)
8.5.2 On-Demand Treatment
8.5.2.1 Historical Trend (2018-2022)
8.5.2.2 Forecast Trend (2023-2028)
8.6 Global Hereditary Angioedema Therapeutic Market by Route of Administration
8.6.1 Intravenous
8.6.1.1 Historical Trend (2018-2022)
8.6.1.2 Forecast Trend (2023-2028)
8.6.2 Subcutaneous
8.6.2.1 Historical Trend (2018-2022)
8.6.2.2 Forecast Trend (2023-2028)
8.6.3 Oral
8.6.3.1 Historical Trend (2018-2022)
8.6.3.2 Forecast Trend (2023-2028)
8.7 Global Hereditary Angioedema Therapeutic Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2022)
8.7.1.2 Forecast Trend (2023-2028)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2022)
8.7.2.2 Forecast Trend (2023-2028)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2022)
8.7.3.2 Forecast Trend (2023-2028)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2022)
8.7.4.2 Forecast Trend (2023-2028)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2022)
8.7.5.2 Forecast Trend (2023-2028)
9 North America Hereditary Angioedema Therapeutic Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
10 Europe Hereditary Angioedema Therapeutic Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2022)
10.1.2 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Historical Trend (2018-2022)
10.2.2 Forecast Trend (2023-2028)
10.3 France
10.3.1 Historical Trend (2018-2022)
10.3.2 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Historical Trend (2018-2022)
10.4.2 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Hereditary Angioedema Therapeutic Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2022)
11.1.2 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Historical Trend (2018-2022)
11.2.2 Forecast Trend (2023-2028)
11.3 India
11.3.1 Historical Trend (2018-2022)
11.3.2 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Historical Trend (2018-2022)
11.4.2 Forecast Trend (2023-2028)
11.5 Australia
11.5.2 Historical Trend (2018-2022)
11.5.2 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Hereditary Angioedema Therapeutic Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2022)
12.1.2 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Historical Trend (2018-2022)
12.2.2 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Historical Trend (2018-2022)
12.3.2 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Hereditary Angioedema Therapeutic Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2022)
13.1.2 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2022)
13.2.2 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Historical Trend (2018-2022)
13.3.2 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Historical Trend (2018-2022)
13.4.2 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Takeda Pharmaceutical Company Limited
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 BioCryst Pharmaceuticals, Inc.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Ionis Pharmaceuticals, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Pharming Group N.V.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 CSL Limited.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Attune Pharmaceuticals, Inc.
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Hereditary Angioedema Therapeutic Market: Key Industry Highlights, 2018 and 2028
2. Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Drug Class (USD Billion), 2018-2022
3. Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Drug Class (USD Billion), 2023-2028
4. Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Treatment Type (USD Billion), 2018-2022
5. Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Treatment Type (USD Billion), 2023-2028
6. Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Route Of Administration (USD Billion), 2018-2022
7. Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Route of Administration (USD Billion), 2023-2028
8. Global Hereditary Angioedema Therapeutic Historical Market: Breakup by Region (USD Billion), 2018-2022
9. Global Hereditary Angioedema Therapeutic Market Forecast: Breakup by Region (USD Billion), 2023-2028
10. North America Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Billion), 2018-2022
11. North America Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Billion), 2023-2028
12. Europe Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Billion), 2018-2022
13. Europe Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Asia Pacific Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Asia Pacific Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Latin America Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Billion), 2018-2022
17. Latin America Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Billion), 2023-2028
18. Middle East and Africa Hereditary Angioedema Therapeutic Historical Market: Breakup by Country (USD Billion), 2018-2022
19. Middle East and Africa Hereditary Angioedema Therapeutic Market Forecast: Breakup by Country (USD Billion), 2023-2028
20. Global Hereditary Angioedema Therapeutic Market Structure
Key Questions Answered in the Report
The global hereditary angioedema therapeutic market reached a value of USD 3.19 billion in 2022.
The market is projected to grow at a CAGR of nearly 8.90% in the forecast period of 2023-2028.
The market is estimated to reach a value of about USD 5.32 billion by 2028.
The major drivers of the industry include the rising disposable incomes, increasing population, and the rising awareness-raising activities among the general population.
The expansion of healthcare sector across emerging economies is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The leading drug classes in the industry are C1-esterase inhibitor, bradykinin B2 receptor antagonist, and kallikrein inhibitor, among others.
The significant treatment types in the market are prophylaxis treatment and on-demand treatment.
The major routes of administration in the industry are intravenous, subcutaneous, and oral.
The leading players in the market are Shire PLC, BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, and Attune Pharmaceuticals, Inc., among others.
Analyst Review
The global hereditary angioedema therapeutic market attained a value of USD 3.19 billion in 2022, driven by the rising awareness-raising activities among the general population. Aided by the growing healthcare and pharmaceuticals sectors, the industry is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 8.90%. The industry is projected to reach USD 5.32 billion by 2028.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on drug class, the global market for hereditary angioedema therapeutic can be segmented into C1-esterase inhibitor, bradykinin B2 receptor antagonist, and kallikrein inhibitor, among others. By treatment type, the industry can be divided into prophylaxis treatment and on-demand treatment. On the basis of route of administration, the industry can be categorised into intravenous, subcutaneous, and oral. The major regional markets for hereditary angioedema therapeutic are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, and Attune Pharmaceuticals, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER